Features | Partner Sites | Information | LinkXpress
Sign In
Biostrata Ltd on behalf of Thermo
PURITAN MEDICAL
FOCUS DIAGNOSTICS, INC.

Newest Combination HIV Antigen-Antibody Assay Evaluated

By Labmedica International staff writers
Posted on 27 Feb 2013
Diagnostic tests capable of early detection represent the most effective means of preventing transmission of human immunodeficiency virus (HIV).

A fourth-generation antigen-antibody combination assay has been developed to allow earlier detection of seroconversion, and has increased sensitivity and improved specificity.

Scientists at the Innsbruck University Hospital (Austria) determined how early the assay could detect infection compared with existing assays; whether all HIV variants could be detected; and the assay's specificity using samples from blood donors, routine specimens, and patients with potential cross-reacting factors.

The study was carried out at 12 centers in Europe, Thailand, and Australia. The Elecsys HIV combi PT assay (Roche Diagnostics; Penzberg, Germany) is performed according to the sandwich principle. The results are automatically determined by the Elecsys software that compares the signal produced from the sample with the cutoff value obtained during system calibration. The total assay time is 27 minutes.

A total of 14 seroconversion panels, comprising 135 samples were analyzed to determine how soon after a positive polymerase chain reaction (PCR) result the immunoassays could detect HIV infection. Samples were identified as positive by the Elecsys assay 4.9 days after a positive PCR result that had been predetermined, which was earlier than the 5.3 to 7.1days observed with other comparable assays. The analytical sensitivity of the Elecsys HIV combi PT assay for the HIV-1 p24 antigen was 1.05 IU/mL, which compares favorably with the other assays.

In addition, the assay identified all screened HIV subtypes and displayed greater sensitivity to HIV-2 homologous antigen and antibodies to HIV-1 E and O and HIV-2 than the other assays. The assay demonstrated 100% specificity in patients with infections other than HIV, such as Cytomegalovirus or herpes simplex virus. Overall, the specificity of the Elecsys assay was 99.88% using samples from blood donors and 99.81% when analyzing unselected samples. Potential cross-reacting factors did not interfere with assay performance. The Elecsys HIV combi PT assay has been granted the European Conformity (CE) marking and is now available for use in laboratory-based testing. The study was published in the February 2013 issue of the journal Medical Microbiology and Immunology.

Related Links:
Innsbruck University Hospital
Roche Diagnostics


77 ELEKTRONIKA
KARL HECHT GMBH & CO KG
CELLAVISION AB

Channels

Clinical Chemistry

view channel
Image: Gas chromatography linked to mass spectrometry apparatus (Photo courtesy of the Hebrew University).

Gastric Cancer Detected Through Exhaled Breath

A new type of technology that senses minute changes in the levels of particular compounds in exhaled breath accurately identifies high risk changes which herald the development of stomach cancer.... Read more

Genetic Tests

view channel

Buccal Swabs Replace Phlebotomy for Postnatal and Pediatric DNA Collection

Collection of samples for prenatal and pediatric DNA sequencing procedures is now available via buccal swabs rather than by phlebotomy. CombiMatrix Corporation (Irvine, CA, USA) a molecular diagnostics company specializing in DNA-based diagnostic services for prenatal, postnatal, and pre-implantation genetic testing... Read more

Industry News

view channel

Bio-Rad Grants Beckman Coulter Exclusive Distribution for Two Infectious Disease Tests

Bio-Rad Laboratories, Inc. (Hercules, CA, USA), a global provider of life science research and clinical diagnostic products, and clinical diagnostics leader Beckman Coulter Diagnostics (Brea, CA, USA), have announced that Bio-Rad is extending its agreement with Beckman Coulter and has named the company exclusive global... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.